A global clinical trial has shown that chimeric antigen receptor (CAR) T cell therapy can lead to long-lasting remissions in patients with relapsed/refractory diffuse large B-cell lymphoma. The treatment, known as Kymriah, modified patients' own immune T cells to target cancer cells and achieved high remission rates.
The phase-2 JULIET trial found that CAR-T cell therapy achieved a 52% favorable response rate in patients with relapsed or refractory diffuse large B-cell lymphoma, with 40% experiencing complete responses. Sixty-five percent of patients remained relapse-free after one year.
Researchers found that checkpoint blockade therapy can sensitize patients to better respond to future use of drugs, even when initial attempts failed. This breakthrough has significant implications for treating relapsing non-Hodgkin lymphoma and Hodgkin lymphoma patients.
A daily hydroxyurea pill has been shown to improve health outcomes for young children with sickle cell anemia in resource-challenged sub-Saharan Africa. The treatment reduced rates of pain episodes, infections, malaria, transfusions, and death by significant margins.
A new study highlights the effectiveness of CAR T-cell therapy in treating diffuse large B cell lymphoma patients. The real-world outcomes show that 81% of patients responded to the therapy with 58% having no detectable cancer after four months.
A 5-year study finds that deep-insulating snowpack loss could reduce forest carbon storage and filter pollutants by 95% in the northeastern US. This decline affects sugar maple trees, impacting industries like timber, maple syrup production, and tourism.
Preliterate 6-year-olds outperformed their peers on grammatical relations, but struggled with novel words. After six months of reading instruction, the advantage disappeared, suggesting that literacy may come at a cost.